Fig. 6

In vivo anti-tumor activity of MMF in patient-derived DIPG xenografted models. A Mice with SF8628 intracranial tumors were either treated with vehicle (DMSO, n = 7) or MMF (50 mg/kg for 15 days, n = 9). Left: Tumor growth curve for bioluminescence values in each treatment group. Tumor bioluminescence values show mean and upper SD. Upper left: Corresponding tumor bioluminescence intensity overlay images for representative DMSO (left) and MMF (right)-treated mice on day 11 post-tumor cell implantation. Right: Corresponding survival plots of each treatment group. B Mice with SF8628 subcutaneous (sc) tumor were either treated with vehicle (DMSO, n = 7) or MMF (100 mg/kg, n = 7) daily for 15 days for 3 weeks. Left: Growth plots for sc tumors in each treatment group. Tumor volumes were normalized against tumor volume obtained at day 6 post-tumor cell injection. Normalized tumor volume show mean and upper SD. Middle: Dot plot representation of sc tumor volume in mice at day 42 post-tumor cell injection. Unpaired t-test values for comparisons between DMSO and MMF treatment: ***P = 0.0002. Photographs of nude mice (upper) and sc tumor taken from these mice (lower) in which SF8628 cells were inoculated into the right flank. Right: Animal survival at the indicated days after inoculation. Log-rank test was used for comparisons between DMSO and MMF treatment: ***P = 0.0003. C Left: Images of representative Ki-67 and TUNEL staining for sc tumors from mice euthanized at the end of treatment. The scale bar is defined as the length of 50 µm. Right, mean and SD values representing the average number in positive cells in four-high-powered fields in each tumor. Statistical analysis was performed using the unpaired t-test. Ki-67: DMSO versus MMF, ***P = 0.0002. TUNEL: DMSO versus MMF, **P = 0.0060